Wegovy
PulseAugur coverage of Wegovy — every cluster mentioning Wegovy across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
Ozempic-maker Novo Nordisk rebrands to 'Novo' amid competition
Novo Nordisk, the pharmaceutical company known for its weight-loss drugs Ozempic and Wegovy, is rebranding to simply 'Novo'. This change aims to make the brand more memorable and relevant for consumers as the company fa…
-
IHH Healthcare CEO launches longevity program amid Asia's aging population
IHH Healthcare, led by CEO Prem Kumar Nair, is launching a new preventive health and longevity program called "Healthspan" to address the growing issue of lifestyle diseases in Asia's aging population. The initiative, c…
-
Medicare GLP-1 discount program excludes patients with certain medical conditions
A new Medicare pilot program offering GLP-1 medications for weight loss at a reduced cost of $50 per month has encountered issues with patient eligibility. While intended to help those struggling with the high price of …
-
GLP-1 drugs transform obesity treatment but affordability crisis looms
GLP-1 drugs like Ozempic, Wegovy, and Zepbound are revolutionizing obesity treatment by shifting focus from late-stage interventions to proactive weight management. These medications have shown significant reductions in…
-
Eli Lilly escalates fight against black market retatrutide
Eli Lilly & Co. is intensifying its efforts to combat the illicit market for retatrutide, an experimental weight-loss drug. The company has filed lawsuits against businesses in the US, particularly in Texas, that are il…
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
Bank of America spends $250M annually on weight loss drugs for staff
Bank of America is significantly investing in employee wellness by spending over $250 million annually on weight loss drugs like Ozempic and Wegovy. CEO Brian Moynihan views this as a crucial investment in employee heal…
-
Companies tap retired CEOs amid succession planning crisis
Companies are increasingly turning to retired CEOs to fill leadership gaps as internal succession pipelines become depleted. This trend is driven by executives staying in their roles longer, leading to potential success…
-
Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground
Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…
-
GLP-1 drugs like Ozempic may cause unlisted side effects, study finds
New research indicates that GLP-1 medications like Ozempic and Wegovy may have side effects not listed on their labels. A study analyzing Reddit posts found that nearly half of semaglutide and tirzepatide users reported…
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
FDA peptide vote could unlock new telehealth market, mirroring Ozempic boom
The FDA's upcoming vote on seven peptides, including BPC-157 and TB-500, could legitimize a new multibillion-dollar market for wellness injectables. Telehealth companies like Hims & Hers, which previously profited from …
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …
-
GLP-1 drugs disrupt diet trends, fueling protein-focused food market
GLP-1 medications are fundamentally altering the food industry, according to David Protein CEO Peter Rahal. He states that traditional diet trends are becoming obsolete as people increasingly turn to these drugs for wei…
-
Medicare to offer weight-loss drugs, straining doctor capacity
Starting next month, Medicare will offer weight-loss drugs like Wegovy and Zepbound for a subsidized price of $50 per month. This initiative is expected to lead to a significant surge in demand, potentially overwhelming…
-
GLP-1 Drugs Could Save Adults Hundreds of Thousands in Medical Costs
A new study from the National Bureau of Economic Research (NBER) suggests that middle-aged adults using GLP-1 drugs for obesity could save over $192,000 in lifetime medical costs. These savings are even higher for indiv…
-
Novo Nordisk hit by cyberattack stealing clinical trial data
Novo Nordisk has reported a cyberattack where hackers stole clinical trial data. The company is investigating the incident, which occurred around the same time the UK approved Wegovy for weight management. This attack h…
-
Health plans balk at paying for GLP-1 weight loss drugs
Health plans and employers are increasingly hesitant to cover GLP-1 drugs for weight loss due to high costs and patient discontinuation rates. A new report indicates that nearly half of employers not currently covering …
-
Eli Lilly launches direct-to-consumer drug sales bypassing PBMs
Eli Lilly has launched LillyDirect, a direct-to-consumer platform for its weight-loss medications like Zepbound, bypassing traditional pharmacy benefit managers (PBMs). This integrated system includes online physician r…
-
Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs
Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…